Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000
hello@breathelifesciences.com
+61 2 9078 8180

27 July 2026

Quarterly Activities Report Period Ending 30 June 2026

Key Highlights

- Record quarterly revenue of **$22.5 million** (5% above previous quarter), delivering FY26 revenue of **$74.98 million** (156% above the prior year), at the top end of the Company's guidance range of $65-75m
- Record FY26 Adjusted EBITDA of $19m[1] (190% above the prior year) at the top end of guidance range of $16.5m - $19m.
- Record positive operating cash flow of **$6.3 million** generated during the quarter
- Cash receipts remained strong at **$20.7 million** for the quarter and **$72.9 million** for FY2026 (125% above FY2025)
- Cash balance increased to **$13.3 million** at 30 June 2026, from $8.5 million at 31 March 2026
- Secured a two-year $50 million pharmaceutical supply agreement with ADREXpharma in Germany, with a $25 million minimum commitment in Year 1
- First international supply of medicinal cannabis flower into Costa Rica, marking BLS's LATAM market entry
- Edward Myer appointed as independent Non-Executive Director, strengthening Board governance
- Completed transition to BLS Pharmaceuticals Limited, reflecting the Company's growth to an international pharmaceutical manufacturing business

BLS Pharmaceuticals Limited (ASX: **BLS**) (“**BLS”** or “**the Company”**), formerly Bioxyne Limited (ASX:BXN), is pleased to report activities for the quarter ended 30 June 2026.

FY26 was a pivotal year for BLS Pharmaceuticals. The Company delivered record financial performance while growing its business into an international pharmaceutical manufacturing and distribution platform. During the year, BLS expanded across Europe and Latin America, secured major commercial agreements, strengthened its Board, invested in manufacturing capability and completed its transition to BLS Pharmaceuticals Limited.

The Company enters FY27 with a significantly larger international platform, growing contracted revenues and a strengthened balance sheet to support its next phase of growth.

[1] FY2026 figures are currently unaudited. Adjusted EBITDA is before Interest, tax, depreciation and amortisation and share based payments

Chief Executive Officer Sam Watson commented:

"FY26 was a defining year for BLS Pharmaceuticals. We met the top end of our financial guidance while continuing to expand internationally and strengthen every part of our pharmaceutical manufacturing platform.

"We have secured major international commercial partnerships, entered new regulated markets, expanded our manufacturing capability and strengthened our balance sheet.

"Our transition to BLS Pharmaceuticals reflects the business we have become, an international pharmaceutical manufacturing and distribution company with growing exposure across medicinal cannabis, controlled substances and emerging regulated therapeutics. We believe FY27 provides another significant opportunity to build on this momentum."

Revenue

BLS delivered record quarterly revenue of $22.5 million, an increase of approximately 5% over the previous quarter and the highest quarterly revenue in the Company's history.

FY26 revenue totalled $74.98 million, at the top end of the Company's guidance range of $65-75 million.

Revenue growth was driven by strong performance across the Australian business, expanding international sales into Europe, continued growth in white label pharmaceutical manufacturing, increasing demand for regulated therapeutic products and the commencement of new international commercial agreements.



Cash Receipts

Customer cash receipts remained strong at **$20.7 million** during the quarter.

BLS generated **$6.3 million** in positive operating cash flow, the strongest result reported by the Company to date, demonstrating the scalability of the Company's manufacturing platform and improving operating economy of scale as revenues continue to grow.

Cash and cash equivalents increased to **$13.3 million** at 30 June 2026, from **$8.5 million** at 31 March 2026.



The Group continued to build its inventory levels based on forecast demand.



The Company continued to invest in manufacturing infrastructure during the quarter, including capital expenditure to support future production capacity and international growth initiatives. This investment was funded while maintaining a strong balance sheet, providing flexibility to continue expanding manufacturing capability, international reach and commercial growth.

INTERNATIONAL EXPANSION

ADREXpharma Germany

During the quarter, BLS executed a landmark two-year pharmaceutical supply agreement with German pharmaceutical company ADREXpharma GmbH valued at approximately **$50 million**, with a minimum purchase commitment of **$25 million** during the first 12 months.

The agreement grants ADREXpharma exclusive rights to distribute the Company's Dr Watson® medicinal cannabis products in Germany, Europe's largest regulated medicinal cannabis market , and represents one of the most significant commercial supply agreements secured by the Company to date, establishing a strong foundation for recurring European revenues.

Latin America Expansion

BLS continued to expand its international footprint through the execution of an expanded supply agreement with Remidose LATAM SRL for the supply of three Dr Watson® medicinal cannabis flower products into Costa Rica.

The agreement represents the Company's first commercial entry into the regulated Costa Rican medicinal cannabis market and broadens BLS's presence across Latin America. The initial commercial sale, valued at more than $500,000, marks an important milestone as BLS continues to pursue additional growth opportunities throughout the region.

Scotland Manufacturing Facility

Development of the Company's GMP pharmaceutical manufacturing facility in Scotland continued with commissioning remaining on schedule for completion by September 2026.

Once operational, the facility will significantly expand BLS's manufacturing capacity and strengthen its ability to supply pharmaceutical products directly into the United Kingdom

Year to date CAPEX on the facility is A$2.1m with A$1.0m in loans and $0.5m in grants received from South of Scottish Enterprise.

Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000
hello@breathelifesciences.com
+61 2 9078 8180

Expanding European Platform

The Company's European operations continued to strengthen throughout FY26, supported by increasing pharmaceutical exports, new commercial partnerships and continued investment in manufacturing capability.

The combination of the ADREXpharma agreement, continued expansion of the Dr Watson® portfolio, growing pharmaceutical distribution capability and the development of the Scotland manufacturing facility, positions BLS as an increasingly diversified international pharmaceutical manufacturer with operations spanning Australia, the United Kingdom, Germany and Latin America.

PHARMACEUTICAL MANUFACTURING

Aurora Manufacturing Agreement

During the quarter, BLS entered into a manufacturing agreement with Aurora Cannabis Inc., one of the world's largest medicinal cannabis companies, for the supply of GMP-certified medicinal cannabis products.

The initial scope includes medicinal cannabis oils for the Australian market and to expand to vape products for Australia, the United Kingdom and Germany. Initial sales covered more than 5,000 units of sublingual oils and more than 20,000 vape products, providing a meaningful foundation for a broader international manufacturing relationship.

The agreement validates BLS's manufacturing capability and positions the Company as a trusted pharmaceutical partner to major global operators seeking access to regulated markets.

Psilocybin Commercialisation

BLS continued to advance the commercialisation of its GMP-manufactured psilocybin capsules, BLSPSIL25, for investigational use in treatment-resistant depression and other mental health conditions.

Initial sales were for supply to authorised prescribers delivering psychedelic-assisted therapy services in Australia. The first sales represented 250 doses, sufficient to support treatment for approximately 60 patients over the following 12 months.

The program establishes BLS as one of the few Australian pharmaceutical manufacturers with the capability to produce and supply GMP-compliant psilocybin in finished-dose form.

Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000
hello@breathelifesciences.com
+61 2 9078 8180

Corporate Development

Board Strengthening

During the quarter, BLS strengthened its Board with the appointment of **Edward Myer** as an Independent Non Executive Director and Independent Chair of the Audit and Finance Committee.

Mr Myer brings extensive experience across corporate finance, investment markets and governance, further enhancing the Board's capability as the Company continues to execute its international growth strategy. His appointment reflects BLS's ongoing commitment to strong corporate governance and disciplined financial oversight as the business continues to scale.

Transition to BLS Pharmaceuticals

Following shareholder approval at the General Meeting held on 19 June 2026, the Company completed its corporate rebrand from **Bioxyne Limited** to **BLS Pharmaceuticals Limited**, with shares commencing trading under the new ASX ticker **BLS** on 7 July 2026.

The name change reflects the Company's evolution from its origins as a diversified life sciences business into an international pharmaceutical manufacturer focused on the development, manufacture and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. The rebrand aligns the Company's corporate identity with its core business, international strategy and long-term growth objectives.

Share Consolidation

As part of the Company's corporate transition, shareholders also approved a **10-for-1 share consolidation**, which became effective on 29 June 2026.

The consolidation formed part of the Company's broader corporate transition and reflected its evolution to BLS Pharmaceuticals Limited.

Corporate

During the quarter the Company received approximately $1.3 million from option holders exercising their options, and $0.5 million in grants from South of Scotland Enterprise.

Capital expenditure during the quarter was $2.6 million, primarily on the Scotland facility, bringing capex to date to $3.7 million as the Company expanded facilities to support the growth of the business.

Suite 506, Level 5 50 Clarence
Street, Sydney NSW 2000

hello@breathelifesciences.com

+61 2 9078 8180

The Company paid directors salaries and fees for the quarter in the amount of $185,000.

Outlook

Following a record FY26, BLS enters FY27 with strong commercial momentum, an expanding international pharmaceutical platform and a strengthened balance sheet.

The Company remains focused on executing its international growth strategy, including the continued ramp-up of the ADREXpharma agreement in Germany, expansion across Europe and Latin America, continued growth in pharmaceutical manufacturing activity, and the completion of its GMP manufacturing facility in Scotland.

Audited FY26 financial results, together with a comprehensive review of the Company's operations and outlook, are scheduled for release on or around Wednesday, 26 August 2026, at which time the Company also plans to release FY2027 guidance.

Approved by the Board of BLS Pharmaceuticals Limited for release to the ASX.

For further information, please contact:

BLS Pharmaceuticals
Sam Watson
Chief Executive Officer
hello@breathelifesciences.com

NWR Communications
Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

About BLS Pharmaceuticals Ltd.

BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products.

BLS maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (BLS) is a wholly owned subsidiary of BLS Pharmaceuticals Limited and a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA.

Established in 2018, BLS has developed an international pharmaceutical manufacturing and distribution platform with operations across Australia, Japan, the United Kingdom and Europe. The business specialises in final dose-form manufacturing, pharmaceutical distribution, contract manufacturing, international supply and the development of regulated therapeutic products.

BLS sources pharmaceutical raw materials and active pharmaceutical ingredients from a global supplier network and manufactures products for both its own brands and third-party customers. The Company owns the Dr Watson® brand portfolio across multiple international markets and supplies pharmaceutical products, active pharmaceutical ingredients and manufacturing services to customers globally.

In addition to its medicinal cannabis operations, BLS holds licences and capabilities supporting the manufacture, import, export and distribution of a range of regulated pharmaceutical products, positioning the business to participate in emerging therapeutic markets, including psychedelic medicines.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

BLS Pharmaceuticals Limited

ABN	**Quarter ended ("current quarter")**
97 084 464 193	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	20,703	72,923
1.2	Payments for		
	(a) research and development	-	(91)
	(b) inventory, product manufacturing and operating costs	(13,597)	(61,502)
	(c) advertising and marketing	(21)	(241)
	(d) leased assets	(26)	(178)
	(e) staff costs (including directors fees)	(513)	(2,155)
	(f) administration and corporate costs	(680)	(4,319)
1.3	Dividends received (see note 3)		
1.4	Interest received	-	79
1.5	Interest and other costs of finance paid	(30)	(137)
1.6	Income taxes paid		
1.7	Government grants and tax incentives	455	1,514
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**6,291**	**5,893**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	(2,569)	(3,715)
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets	(99)	(217)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material) cash on acquisition of subsidiary		
2.6	**Net cash from / (used in) investing activities**	**(2,668)**	**(3,932)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,319	1,447
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings (lease)/other		2,554
3.6	Loan to third party		
3.7	Repayment of borrowings	(105)	(296)
3.8	Dividends paid		
3.9	Other – bank guarantee	(73)	(86)
3.10	**Net cash from / (used in) financing activities**	**1,141**	**3,619**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	8,490	7,668
4.2	Net cash from / (used in) operating activities (item 1.9 above)	6,291	5,893
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2,668)	(3,932)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,141	3,619
4.5	Effect of movement in exchange rates on cash held	4	10
4.6	**Cash and cash equivalents at end of period**	**13,258**	**13,258**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	13,258	8,490
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**13,258**	**8,490**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	185
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

The amount in item 6.1 represents director's fees and salaries.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	(1) 665 (2) 1,005 (3) 3,000	665 1,005 Nil
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**	4,670	1,670

7.5	**Unused financing facilities available at quarter end**	Nil

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

(1) NAB, term to 30 June 2028, unsecured, interest 8%
(2) South of Scotland Enterprise, 60 months to December 2030, unsecured, interest 9.5%
(3) Overdraft facility Westpac executed 10 July 2026

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	5,899
8.2	Cash and cash equivalents at quarter end (Item 4.6)	13,258
8.3	Unused finance facilities available at quarter end (Item 7.5)	3,000
8.4	Total available funding (Item 8.2 + Item 8.3)	16,258
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2026..

Authorised by: ..The Board..
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.